CoDon EBIT Margin

What does CoDon do? co.don AG develops and sells cell-based biological drugs for regenerative medicine, focusing on orthopedic and neurosurgical applications. Its key products include co don chondrotransplant for knee cartilage defects, co don chondrosphere for three-dimensional cartilage cultivation, co don chondrotransplant DISC for intervertebral disc regeneration, and co don osteotransplant DENT for dental bone cell transplants. The company targets medical professionals and clinics in Germany and other European countries, with its products treating conditions like focal cartilage defects, lumbar disc herniation, non-union fractures, and dental disorders. co.don AG generates revenue through direct sales of these specialized biological drugs to healthcare providers. The firm operates with a product portfolio centered on autologous cell therapies, where patient-derived cells are cultivated for personalized treatments. co don chondrotransplant DISC addresses spinal disc issues, while co don osteotransplant DENT serves dental applications, expanding the company's reach beyond orthopedics. All products are manufactured in-house and sold directly to medical institutions across Europe, with no mention of third-party distribution or additional revenue streams in the business description. co.don AG's revenue model relies on the commercialization of its four primary product lines, each addressing specific medical conditions. The company's focus on regenerative treatments for cartilage, disc, and dental applications ensures a steady demand from clinics specializing in these areas. Sales are conducted within Germany and other European markets, with no indication of global expansion or additional segments beyond the described product uses. CoDon is one of the most popular companies on Eulerpool.